Overview of cabozantinib (Cabometyx) treatment for liver cancer

Cabometyx (Cabometyx), a highly effective anti-cancer drug targeting multiple kinase targets, has achieved remarkable results in the treatment of hepatocellular carcinoma (HCC) in recent years, especially providing a new treatment option for patients with liver cancer that has progressed after sorafenib treatment. Below is an overview of key information about the use of cabozantinib for patients with liver cancer.

1. Medication guidance

1. Dosage and administration: For eligible patients with hepatocellular carcinoma, it is recommended to take cabozantinib 60 mg orally daily, which needs to be separated from food. It is recommended to take it at least 1 hour before a meal or at least 2 hours after a meal to ensure the best efficacy. The medicine should be swallowed whole and avoid crushing or chewing.

2. Handling of missed doses: If you miss a dose, you do not need to take it within 12 hours. You should continue to take the next dose as originally planned to maintain a stable blood concentration.

2. Drug acquisition and cost considerations

1. Market status: Cabozantinib has been launched in many countries, but the price of the original drug is high, reaching tens of thousands of yuan per box, which puts great financial pressure on patients.

2. Economic choice: The cabozantinib version provided by Lucius Pharmaceuticals in Laos is priced at 20 mg * 90 tablets per box, priced at more than 800 yuan, which greatly reduces the burden on patients.

3. Purchasing advice: Choose formal channels to purchase to ensure reliable sources of drugs, verify the authenticity of the drugs, and ensure the safety of treatment.

3. Treatment precautions

1. Individual differences: Although cabozantinib brings hope to many patients, the therapeutic effect varies depending on individual differences. Before treatment, a comprehensive assessment of the condition should be carried out, and a personalized treatment plan should be formulated by a professional doctor.

2. Monitoring and feedback: During the treatment period, physical conditions, including liver and kidney function, blood routine, etc., need to be monitored regularly, and any discomfort or abnormalities should be reported to the doctor in a timely manner so that the treatment plan can be adjusted.

3. Follow the doctor’s instructions: Strictly follow the dosage and method of medication instructed by the doctor, and do not make adjustments on your own to ensure the effectiveness and safety of the treatment.

In summary, cabozantinib, as a new multi-target anticancer drug, shows broad prospects in the treatment of liver cancer. Through the medication guidance provided in this overview, we hope to help liver cancer patients better understand and use this drug.